Publication | Closed Access
Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease
53
Citations
23
References
1995
Year
The relapse rates of Crohn's disease were similar for up to 12 months in both the 5-ASA 1.5 g b.d. and the placebo treatment groups.
| Year | Citations | |
|---|---|---|
Page 1
Page 1